BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22112600)

  • 21. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
    Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
    Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effect of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin lymphomas.
    Lascaux AS; Hemery F; Goujard C; Lesprit P; Delfraissy JF; Sobel A; Lepage E; Lévy Y
    AIDS Res Hum Retroviruses; 2005 Mar; 21(3):214-20. PubMed ID: 15795527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
    Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
    Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study.
    Castillo JJ; Beltran BE; Bibas M; Bower M; Collins JA; Cwynarski K; Diez-Martin JL; Hernandez-Ilizaliturri F; Horwitz SM; Montoto S; Pantanowitz L; Ribera JM; Vose JM
    Am J Hematol; 2011 Mar; 86(3):256-61. PubMed ID: 21328430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modern management of non-Hodgkin lymphoma in HIV-infected patients.
    Mounier N; Spina M; Gisselbrecht C
    Br J Haematol; 2007 Mar; 136(5):685-98. PubMed ID: 17229246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
    Weiss R; Mitrou P; Arasteh K; Schuermann D; Hentrich M; Duehrsen U; Sudeck H; Schmidt-Wolf IG; Anagnostopoulos I; Huhn D
    Cancer; 2006 Apr; 106(7):1560-8. PubMed ID: 16502436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease.
    Gabarre J; Marcelin AG; Azar N; Choquet S; Lévy V; Lévy Y; Tubiana R; Charlotte F; Norol F; Calvez V; Spina M; Vernant JP; Autran B; Leblond V
    Haematologica; 2004 Sep; 89(9):1100-8. PubMed ID: 15377471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients.
    Tanaka PY; Calore EE
    Pathol Res Pract; 2007; 203(1):1-7. PubMed ID: 17157997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
    Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P
    Cancer; 2004 Jul; 101(2):317-24. PubMed ID: 15241829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.
    Crosswell HE; Bergsagel DJ; Yost R; Lew G
    Pediatr Blood Cancer; 2008 Apr; 50(4):883-5. PubMed ID: 17278123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new prognostic score for AIDS-related lymphomas in the rituximab-era.
    Barta SK; Xue X; Wang D; Lee JY; Kaplan LD; Ribera JM; Oriol A; Spina M; Tirelli U; Boue F; Wilson WH; Wyen C; Dunleavy K; Noy A; Sparano JA
    Haematologica; 2014 Nov; 99(11):1731-7. PubMed ID: 25150257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy.
    Castillo JJ; Furman M; Beltrán BE; Bibas M; Bower M; Chen W; Díez-Martín JL; Liu JJ; Miranda RN; Montoto S; Nanaji NM; Navarro JT; Seegmiller AC; Vose JM
    Cancer; 2012 Nov; 118(21):5270-7. PubMed ID: 22510767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.
    Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K
    AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study.
    Schommers P; Wyen C; Hentrich M; Gillor D; Zoufaly A; Jensen B; Bogner JR; Thoden J; Wasmuth JC; Fätkenheuer G; Hoffmann C
    AIDS; 2013 Mar; 27(5):842-5. PubMed ID: 23574794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Prognostic Score Including the CD4/CD8 for AIDS-Related Lymphoma.
    Chen J; Liu X; Qin S; Ruan G; Lu A; Zhang J; Wu Y; Xie Z; Peng J
    Front Cell Infect Microbiol; 2022; 12():919446. PubMed ID: 35873145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response.
    Mélet J; Mulleman D; Goupille P; Ribourtout B; Watier H; Thibault G
    Arthritis Rheum; 2013 Nov; 65(11):2783-90. PubMed ID: 23918413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.